Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
2 clinical trials · Condition
◉ Watch Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study (NCT06805812) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2023-05-01 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors (NCT01576666) | Novartis Pharmaceuticals | 2012-07-01 |
Track Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.